The practical use of acetylsalicylic acid in the era of the ASPRE trial. Update and literature review

Przemysław Kosinski¹, Urszula Sarzynska-Nowacka¹, Magdalena Fiolna², Miroslaw Wielgos¹

¹¹st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland
²Fetal Medicine Unit, Medway Maritime Hospital, Gillingham, Kent, United Kingdom

ABSTRACT
It is now well established that acetylsalicylic acid — one of the most widely prescribed drugs today — has brought a new era in maternal-fetal medicine. The History of medicine mentions several antecedents. Extracts made from willow contained in clay tablets are reported in both ancient Sumer and Egypt. In 400 BC, Hippocrates referred to the use of salicylic tea to reduce fevers. In the 1950s, acetylsalicylic acid entered the Guinness Book of Records as the highest selling painkiller. There is little doubt that acetylsalicylic acid — one of the first drugs to enter common usage — remains one of the most researched drugs in the world.

INTRODUCTION
Hypertension complicates approximately 10% of all pregnancies, including 2–3% of preeclamptic gestations [1]. Preeclampsia (PE) remains a major concern for all obstetricians around the world. It is a systemic vascular disorder, characterized by the onset of hypertension in a previously normotensive patient, and is accompanied by proteinuria or multiple organ failure, developing after 20 weeks of gestation.

Contributing causes of PE development include: abnormal transformation of the spiral arteries during placentaion, impaired placental perfusion, hypoxia, and ischemia (which results in an excess of angiogenic factors, i.e. soluble fms-like tyrosine kinase [sFlt-1] and soluble endoglin [sEng], which lead to increased vascular permeability and blood vessel contraction, as well as the activation of a coagulation cascade). Analysis of the blood flow in maternal arteries is a good detector of pregnant women at a high-risk of PE. Blood flow resistance in maternal arteries decreases in the course of an uncomplicated pregnancy and significantly increases in patients with a high risk of PE [2]. As a result, hypertension, proteinuria, and other clinical manifestations have been observed [3]. Acetylsalicylic acid appeared at the end of the 19th century as a synthetic analgesic agent with improved gastric tolerability vs. naturally occurring salicylates. It was marketed as aspirin in 1899 and turned out to be a good antiplatelet agent. Not so long ago, it was also described as a safe and effective drug to reduce the rate of PE in high-risk pregnant women [3, 4].

ACETYLSALICYLIC ACID IN FETAL MEDICINE
Following reports on aspirin as an effective anti-inflammatory and anti-platelet agent, observational studies on pregnant women were performed. Crandon and Isherwood (1979) showed that a regular intake of aspirin was linked to a lower incidence of PE. Beaufils et al. (1985) suggested that antiplatelet therapy — given early in pregnancy to high-risk patients — may protect against PE and fetal growth restriction [5]. PE is still a common cause of both maternal and fetal complications. The only effective method of treatment — delivery — results in prematurity and the subsequent complications. Therefore, preventive measures are of the utmost importance to lower the risk of PE. The pathogenesis is complex and all interventions so far have not generated...
the expected results in the general population of pregnant women. Low doses (60–150 mg) of acetylsalicylic acid in high-risk patients seem to be the only effective method. It has been observed that PE is associated with elevated levels of platelet thromboxane, which led to a number of studies on the role of acetylsalicylic acid in disease prevention among high-risk women. In contrast to high doses, low doses (60–150 mg) of acetylsalicylic acid reduce thromboxane production, while preserving the synthesis of prostacyclin in the vascular walls [6]. In 1982, the inhibition of prostacyclin formation was alleged to be a facilitator of both thrombosis and obstetrical problems in patients with lupus anticoagulant. This opened a new chapter in maternal-fetal medicine — a prophylaxis of conditions named thrombophilia. Aspirin in low doses is the single most cost-effective medicine for the prevention of the secondary events of thrombosis [7].

ASPIRIN — A “NEW” MECHANISM OF ACTION

Since acetylsalicylic acid is long established as an analgesic, antipyretic, and antiplatelet drug, alternative modes of action have received insufficient recognition, up until now. Interestingly, aspirin induces the production of pro-resolving lipid-derived mediators — similar to endogenous mediators. These biochemical agents are built from arachidonic acid (AA), omega-3 polyunsaturated fatty acids (PUFAs), and aspirin-triggered lipoxins (ATLs), binding to a dedicated receptor (ALXR) [7]. ATLs act as antioxidant and immunomodulators, promoting inflammation resolution, and inhibiting blood vessel proliferation [7, 8]. Increases of both ALXR expression in the human decidua, and of serum lipoxin A4 level during the first trimester of pregnancy, may be a starting point in the understanding of aspirin effectiveness in PE or placental pathologies [9]. It is hypothesized that early (before 34 + 0 weeks, around 20% of cases) and late (after 34 + 0 weeks, around 80% of cases) onset PE have different etiologies, but a common place of origin — the placenta [10]. Considering the high prevalence of PE, and its serious complications both for mothers and newborns, prediction and prophylaxis represent twin-challenges in modern obstetrics.

CIRCADIAN TIMING OF ASPIRIN

Chronology in aspirin administration was once an issue. A double-blind placebo-controlled trial on pregnant women at high risk of PE, and a prospective trial on patients with untreated mild hypertension, both concluded that a low-dose of acetylsalicylic acid lowers blood pressure when administered at bedtime and not on waking [16, 17]. In another trial, the authors conducted a prospective, randomized, double-blind, placebo-controlled, chronotherapy trial on 350 high-risk pregnant women 13.5 ± 1.4 weeks of gestation at the time of recruitment [18], finding that a low-dose aspirin ingested at bedtime, but not on waking, significantly regulates ambulatory blood pressure and reduces the incidence of PE, gestational hypertension, preterm delivery, and IUGR. Interestingly, the described effect was expressed to a larger extent in women, patients with elevated fasting glucose, and a high glomerular filtration rate [19].

VALUABLE NOT ONLY IN PREECLAMPSIA

Fetal growth restriction (FGR) and PE are thought to be different syndromes of the same disorder: placental dysfunction. Ness and Sibai hypothesized that endothelial dysfunction precedes abnormal placentation, and that both are cornerstones of PE and FGR pregnancies. They suggest that the particular clinical manifestation is determined by certain metabolic disturbances [20].

A low aspirin dosage (50–150 mg/day) — started 16 weeks before gestation in high-risk woman — was associated with a significant reduction in perinatal death and FGR, with a mean birth weight increment of 209 g (95% CI: 100–319) [21]. A meta-analysis of 17 randomized trials showed a 50% reduction of FGR risk (RR: 0.47; 95% CI: 0.36–0.62, P < .01) using 60–150 mg of aspirin/day [22].
THE NEW ERA OF PE PROPHYLAXIS
— THE ASPRE STUDY

Although many studies have demonstrated the benefits of aspirin administration during pregnancy, the first randomized controlled trials failed to prove any remarkable advantages of such prophylaxis [23]. For this reason, a large, multicentre randomized, placebo-controlled European Trial (ASPRE) was conducted by Professor Kypros Nicolaides of King’s College Hospital in London. The results have recently been published in The New England Journal of Medicine [24].

A group of 1776 women in singleton pregnancies, at a high risk of PE, were randomly assigned to receive either aspirin at a dose of 150 mg or placebo, starting from 11 to 14 weeks of gestation until 36 weeks of gestation. The study was designed to answer the question regarding aspirin influence on PE, which arose from ambiguous meta-analyses. Firstly, the authors took an alternative approach to their screening method, the effectiveness of which was validated in a study involving approximately 60,000 women. The combined mult-marker screening is a combination of a priori risk together with medical information acquired at 11–13 weeks of gestation, employing Bayes’ theorem. This detects 76% of preterm cases and 38% of term PE [25]. The trial was distinguished from other aspirin-based studies by the high accuracy across the range of high-risk patients. The variables calculated in the algorithm were: age, height, weight, racial origin, chronic hypertension, systemic lupus erythematosus or antiphospholipid syndrome, method of conception, parity in regard to the history of PE and intergestational interval, family history of PE, diabetes mellitus type 1 or 2, cigarette smoking, mean arterial pressure, uterine artery pulsatility index, pregnancy associated plasma protein-A (PAPP-A), and

| Table 1. Selected organization guidance on patients who are appropriate candidates for the use of different low-doses of aspirin to prevent preeclampsia (modified from Jackson&Gregg 2017 [12] ) |
|---------------------------------|------------------|--------------------|------------------|------------------|
| **High risk > 1** | | | |
| History of PE | x | x | x | x |
| Multifetal gestation* | x | x | — | x |
| Chronic hypertension | x | x | x | x |
| Diabetes type 1 or 2 | x | x | x | x |
| Renal disease | x | x | x | x |
| Autoimmune disease | x | x | x | x |
| **Moderate risk > 1** | | | |
| Nulliparous | x | — | x | — |
| Age > 40 years | — | — | x | — |
| > 10 years IPI | x | — | x | — |
| First degree relative | x | — | x | — |
| BMI >35 kg/m2 | — | — | x | — |
| Multifetal gestation | — | — | x | — |
| Low SES | x | — | — | — |
| Age > 35 years | x | — | — | — |
| BMI > 30 kg/m2 | x | — | — | — |
| Patient born LBW | x | — | — | — |
| Prior APO | x | — | — | — |

ACOG — American College of Obstetricians and Gynecologists; APO — adverse pregnancy outcome (not specifically defined); BMI — body mass index; IPI — interpregnancy interval; LBW — low birth weight; NICE — National Institute for Health and Care Excellence (United Kingdom); PE — physical education; SES — socioeconomic status (not specifically defined); USPTF — U.S. Preventive Services Task Force; WHO — World Health Organization

* Multifetal gestation is not a high-risk factor but is a moderate-risk factor in the NICE guidance.

** Moderate-risk factors are those with less than 8% risk. NICE proposes 2 or more for aspirin prophylaxis.
placental growth factor (PIGF). Moreover, the authors looked for preterm rather than total PE. A threshold for “high-risk” pregnancy was established at > 1:100 and delivery with PE before 37 weeks of gestation was measured as a primary outcome. The participants were randomly assigned to aspirin or placebo groups, in a 1:1 ratio. PE before 37 weeks’ gestation was diagnosed in 13 of 798 (1.6%) patients in the aspirin group and 35 of 822 (4.3%) in the placebo group (adjusted odds ratio in the aspirin group — 0.38; 95% CI: 0.2 to 0.74; P = 0.004). The trial was not sufficiently powered for secondary outcomes; nevertheless, the incidence of pregnancy, or fetal or neonatal complications, were similar in both groups. The authors chose aspirin at a dose of 150 mg, on the basis of a previously justified dose-dependent therapeutic benefit. In conclusion, 150 mg of aspirin given at bedtime at 11 to 14 weeks of gestation, until 36 weeks, significantly lowered the incidence of developing preterm PE, compared to placebo, providing a basis to unify recommendations on aspirin commencement. It is worth mentioning that, in this study, aspirin did not lower the risk of term PE.

Based on the conducted studies and histopathological observations, it seems justified to initiate treatment before 16 weeks of gestation as placental implantation and formation of the maternal spiral arteries are completed between 16 and 20 weeks of gestation. Thus, it seems that the beneficial effect of acetylsalicylic acid is the consequence of improved spiral artery transfer [21]. This hypothesis is based on two factors: i) low doses of acetylsalicylic acid are most effective where early pregnancy PE prevention is concerned, which is mostly connected with impaired placental implantation [26], and ii) abnormal blood flow in maternal arteries — already observed at 12 weeks of gestation, in women who will later develop PE — significantly improves between the first and the second trimester in patients receiving acetylsalicylic acid.

**SUMMARY**

Preeclampsia remains one of the most serious complications in pregnancy. Hopefully, in the near future, patients attending their first visit (between 12–14 weeks of gestation) will be offered screening tests for both PE and genetic abnormalities. The current state of knowledge suggests that only pre-selected high-risk patients should receive preventive low-doses of acetylsalicylic acid. Resistance to acetylsalicylic acid remains an area of debate. As many as 30% of pregnant women are suspected to be aspirin-resistant. For this reason, in centres such as King’s College Hospital, a dosage of 150 mg of acetylsalicylic acid at bedtime is used, which is a compromise between the dose being effectively therapeudic and the risk of possible adverse effects. The belief that PE is a condition limited to pregnancy — with the risk of termination after placenta removal — is no longer held true. Women with a history of PE have an increased risk of ischemic heart disease, stroke, cerebrovascular disease, peripheral arterial disease, cardiovascular mortality and death from stroke, chronic hypertension, end-stage renal disease, and metabolic disorders. Aspirin is a well-known preventive agent diminishing the risk of many of these conditions. Future research could be focussed on post-pregnancy aspirin use. At the same time, it is important to emphasize that screening for PE and pharmacological prophylaxis using acetylsalicylic acid requires further, multi-centre randomized trials in order to implement both screening tests and preventative measures into daily clinical practice.

**REFERENCES**


